blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2236135

EP2236135 - STABLE PHARMACEUTICAL COMPOSITION [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  03.03.2017
Database last updated on 02.11.2024
Most recent event   Tooltip03.03.2017Withdrawal of applicationpublished on 05.04.2017  [2017/14]
Applicant(s)For all designated states
Asahi Kasei Pharma Corporation
1-105 Kanda Jinbocho Chiyoda-ku
Tokyo 101-8101 / JP
[2010/40]
Inventor(s)01 / SUZUKI, Kazumi
1-105 Kanda Jinbocho Chiyoda-ku
Tokyo 101-8101 / JP
 [2010/40]
Representative(s)Forstmeyer, Dietmar, et al
Boeters & Lieck
Oberanger 32
80331 München / DE
[N/P]
Former [2010/40]Forstmeyer, Dietmar, et al
Boeters & Lieck Oberanger 32
D-80331 München / DE
Application number, filing date09702201.616.01.2009
[2010/40]
WO2009JP50512
Priority number, dateUS2008002191018.01.2008         Original published format: US 21910
[2010/40]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009091017
Date:23.07.2009
Language:JA
[2009/30]
Type: A1 Application with search report 
No.:EP2236135
Date:06.10.2010
Language:EN
[2010/40]
Search report(s)International search report - published on:JP23.07.2009
(Supplementary) European search report - dispatched on:EP02.04.2012
ClassificationIPC:A61K31/196, A61K31/404, A61K31/416, A61K47/26, A61K47/36, A61K47/38, A61K9/20, A61K31/4365, A61K31/60
[2012/14]
CPC:
A61K31/196 (EP,KR,US); A61K31/404 (EP,KR,US); A61K31/416 (EP,KR,US);
A61K31/4365 (EP,US); A61K31/60 (EP,US); A61K47/36 (EP,KR,US);
A61K47/38 (EP,US); A61K9/2018 (EP,US); A61K9/2027 (EP,US);
A61K9/2054 (EP,US); A61K9/2059 (EP,US); A61P25/04 (EP);
A61P29/00 (EP); A61P29/02 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/4365, A61K2300/00 (EP,US);
A61K31/60, A61K2300/00 (US,EP)
Former IPC [2010/40]A61K31/196, A61K31/404, A61K31/416, A61K47/26, A61K47/36, A61K47/38
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/40]
TitleGerman:STABILE PHARMAZEUTISCHE ZUSAMMENSETZUNG[2010/40]
English:STABLE PHARMACEUTICAL COMPOSITION[2010/40]
French:COMPOSITION PHARMACEUTIQUE STABLE[2010/40]
Entry into regional phase15.07.2010Translation filed 
15.07.2010National basic fee paid 
15.07.2010Search fee paid 
15.07.2010Designation fee(s) paid 
15.07.2010Examination fee paid 
Examination procedure15.07.2010Examination requested  [2010/40]
24.10.2012Amendment by applicant (claims and/or description)
12.12.2013Despatch of a communication from the examining division (Time limit: M06)
02.05.2014Reply to a communication from the examining division
14.10.2015Despatch of a communication from the examining division (Time limit: M04)
01.02.2016Reply to a communication from the examining division
24.02.2017Application withdrawn by applicant  [2017/14]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  12.12.2013
Fees paidRenewal fee
14.01.2011Renewal fee patent year 03
11.01.2012Renewal fee patent year 04
10.01.2013Renewal fee patent year 05
21.01.2014Renewal fee patent year 06
13.01.2015Renewal fee patent year 07
11.01.2016Renewal fee patent year 08
11.01.2017Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]EP1477472  (ASAHI KASEI PHARMA CORP [JP]) [X] 1,2,4-13,15-19 * abstract * * paragraphs [0192] - [0193] * * sentences 40-41, paragraph 89 * * paragraphs [0717] , [0722] , [0727] , [0731] * [Y] 1-20;
 [XY]WO2005016862  (ASAHI KASEI PHARMA CORP [JP], et al) [X] 1,2,4-13,15-19 * abstract * * page 396, paragraph last - page 397, paragraph 3 * * test examples; page 654 - page 664 * [Y] 1-20;
 [XP]WO2008010448  (ASAHI KASEI PHARMA CORP [JP], et al) [XP] 1,2,4-13,15-19 * abstract * * paragraph [0164]; example 9 * * paragraphs [0098] - [0099] * * claims 1-23 *;
 [Y]US2004138180  (AHMED SALAH U [US], et al) [Y] 1-20 * abstract * * paragraphs [0005] - [0007] * * paragraph [0045] * * paragraphs [0051] - [0061] * * claims *;
 [Y]US2006093631  (BUEHLER GAIL K [US]) [Y] 1-20 * abstract * * paragraphs [0024] - [0027] * * paragraph [0040] * * claims *;
 [Y]EP0879048  (QUADRANT DRUG DELIVERY LTD [GB]) [Y] 1-20 * abstract * * paragraphs [0021] - [0022] * * claims *
 [Y]  - DIFEO THOMAS J, "Drug product development: a technical review of chemistry, manufacturing, and controls information for the support of pharmaceutical compound licensing activities.", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY OCT 2003 LNKD- PUBMED:14606659, (200310), vol. 29, no. 9, ISSN 0363-9045, pages 939 - 958, XP002669515 [Y] 1-20 * page 942, column l, lines 31-39 *

DOI:   http://dx.doi.org/10.1081/DDC-120025452
 [Y]  - STEPHEN R BYRN ET AL, "Chemical reactivity in solid-state pharmaceuticals: formulation implications", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 48, no. 1, doi:10.1016/S0169-409X(01)00102-8, ISSN 0169-409X, (20010516), pages 115 - 136, (20010420), XP002628347 [Y] 1-20 * abstract * * page 130, column l, line 7 - column r, line 11 *

DOI:   http://dx.doi.org/10.1016/S0169-409X(01)00102-8
 [Y]  - BEACHAM H H ET AL, "Some observations on the browning reaction", FOOD RESEARCH 1951, (1951), vol. 16, no. 5, pages 439 - 445, XP002669516 [Y] 1-20 * the whole document *
 [Y]  - HODGE ET AL, "Chemistry of Browning Reactions in Model Systems", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (19531001), vol. 1, no. 15, doi:10.1021/JF60015A004, ISSN 0021-8561, pages 928 - 943, XP009140802 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1021/jf60015a004
International search[YP]WO2008010448  (ASAHI KASEI PHARMA CORP [JP], et al);
 [Y]WO2005016862  (ASAHI KASEI PHARMA CORP [JP], et al);
 [Y]WO03070686  (ASAHI CHEMICAL IND [JP], et al);
 [Y]JP2004513093  (CAMBRIDGE BIOSTABILITY LTD.);
 [Y]JP2000505801  (QUADRANT HOLDINGS CAMBRIDGE LTD.);
 [Y]JPH10505591  (QUADRANT HOLDINGS CAMBRIDGE LTD.)
by applicantWO03070686
 WO2005016862
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.